

PRESS RELEASE



ExonHit's extraordinary shareholders' meeting

- The quorum was not reached on first notice
- Another meeting will be held, upon second notice, on Thursday, July 8, 2010, at 16:00 CET, at Company's headquarters

Paris, France – June 30, 2010 – The extraordinary shareholders' meeting convened on June 28 to vote on the acquisition of RedPath Integrated Pathology was not able to deliberate for lack of quorum.

Another extraordinary shareholders' meeting will be convened and held on second notice, on Thursday, July 8, 2010, at 16:00 CET, at Company's headquarters in Paris (63-65 Bd Masséna, 75013 Paris).

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast emerging healthcare player active in both therapeutics and diagnostics. The Company is applying its proprietary technology, based on the analysis of alternative RNA splicing, to develop innovative molecular diagnostic tests and therapeutics for Alzheimer's disease and cancer indications. ExonHit has a balanced investment strategy with internal development programs and strategic collaborations, in particular with bioMérieux and Allergan.

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The Company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

Contact for Media & Investors

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com